Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer? [FOCUS ON QUALITY]

Conclusion:
Using a willingness-to-pay threshold of $100,000 ICER, the addition of BEV to chemotherapy either demonstrates or approaches cost-effectiveness and NHB when added to the treatment of patients with PROC.

Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Chappell, N. P., Miller, C. R., Fielden, A. D., Barnett, J. C. Tags: Cost of care, Chemotherapy FOCUS ON QUALITY Source Type: research